Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  6. News
  7. Summary
    ABVX   FR0012333284


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abivax : publishes Universal Registration Document 2021 'Document d'Enregistrement Universel'

04/30/2021 | 12:01pm EDT

DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax publishes Universal Registration Document 2021 'Document d'Enregistrement Universel'

30.04.2021 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax publishes Universal Registration Document 2021 "Document d'Enregistrement Universel"

PARIS, France, April 30, 2021 - 06:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today the publication of its 2021 Universal Registration Document (Document d'Enregistrement Universel 2021), filed with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), on April 30, 2021.

The Registration Document includes the 2020 Annual Report and the corporate governance report, prepared by the Board of Directors, as well as the conclusions of the statutory auditors.

Copies of the document are available free of charge at the Abivax headquarters on 5, rue de la Baume, 75008 Paris as well as in electronic form via the website of both Abivax (www.abivax.com) and the French Financial Market Authorities (www.amf-france.org). An English translation of the Universal Registration Document will be available on May 7, 2021 at the latest.


About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.


Didier Blondel
+33 1 53 83 08 41
Regina Jehle
+33 6 24 50 69 63
LifeSci Advisors
Chris Maggos
+41 79 367 6254
Public Relations & Investors Europe
MC Services AG
Anne Hennecke
+49 211 529 252 22
Public Relations France
Ghislaine Gasparetto
+33 1 56 88 11 22
Public Relations USA
Rooney Partners LLC
Marion Janic
+1 212 223 4017


This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

30.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

1190876  30.04.2021 


ę EQS 2021
All news about ABIVAX
06/07Abivax annonce les résultats de son Assemblée générale ordinaire annuelle et ..
06/07PRESS RELEASEá : Abivax releases the results of its June 4, 2021 ordinary annual..
06/07ABIVAXá : releases the results of its June 4, 2021 ordinary annual and extraordi..
05/27Affluent Medical lance son introduction en bourse -2-
05/27Affluent Medical launches its IPO on the -2-
05/25ABIVAXá : Surges 40% After Ulcerative Colitis Drug Demonstrates Efficacy In Mid-..
05/24Abivax annonce d'excellents résultats -3-
05/24Abivax annonce d'excellents résultats -2-
05/24Abivax annonce d'excellents résultats d'efficacité et de tolérance d'ABX464 d..
05/24PRESS RELEASE : Abivax reports excellent efficacy -3-
More news
Sales 2021 99,4 M 120 M 120 M
Net income 2021 8,70 M 10,5 M 10,5 M
Net Debt 2021 37,4 M 45,3 M 45,3 M
P/E ratio 2021 -14,5x
Yield 2021 -
Capitalization 437 M 530 M 530 M
EV / Sales 2021 4,77x
EV / Sales 2022 690x
Nbr of Employees 27
Free-Float 55,2%
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 6
Average target price 53,30 €
Last Close Price 30,50 €
Spread / Highest target 244%
Spread / Average Target 74,8%
Spread / Lowest Target -27,9%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
CELLTRION, INC.-21.73%32 458
SEAGEN INC.-10.60%28 416